Lipid in Medical Technology
Navigation Links
Lipid in Medical Technology
... diseases utilizing the principles of Applied lipid Polymorphism , which includes a revolutionary ... nanobiotechnology in the area of self-organizing lipid membranes. Nanoveson(TM) therapy utilizes only ... remodeling into bile phospholipids and lipid membrane fusion and aggregation in the ....
... TRILIPIX 135 mg alone in patients with multiple lipid problems. Results from this new Phase III study ... combination of a fibrate with a statin to improve lipid levels. In the clinical trial, TRILIPIX ... More than 100 million American adults have lipid problems, and 35 percent reported being treated ...
... (rosuvastatin calcium) Demonstrates Similar lipid Effects in Patients with Diabetes and Overall ... This study, presented at the National lipid Association annual meeting on May 31, 2008, met ... in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had ...
... III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) ... III study were presented today at the National lipid Association's 2008 Scientific Sessions in ... Patients included in the study had multiple lipid problems, with an LDL greater than or equal to ...
... uses near-infrared spectroscopy to identify lipid core containing plaques of interest in the ... effect of novel anti-atherosclerotic agents on lipid core plaque burden. "The InfraReDx team is ... "There is a real unmet medical need to identify lipid core containing plaques of interest in the ...
... III studies show that in patients with multiple lipid problems, Abbott's ABT-335 combined with two ... Patients included in the studies had multiple lipid problems, with an LDL greater than 130 ... clinical development for treating unhealthy lipid levels, including LDL cholesterol, triglycerides ...
... also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and ... were also measured with regard to efficacy, lipid effects, safety and tolerability. Additional ... in patients in the lopinavir/r arm. lipid Effects * Seven percent of patients in the ...
... XVI International Symposium on Drugs Affecting lipid Metabolism (DALM) (October 4-7, 2007, New York, ... interactions with five commonly prescribed lipid lowering compounds, opening the possibility for ... for the treatment of dyslipidemia (abnormal lipid levels in the bloodstream). Inhibiting the MTP ...
... provides additional important data on the effect of VIRAMUNE on patient lipid profiles in antiretroviral naive patients." Efficacy Data ... and efficacy of once-daily dosing have not been established. lipid Profile Data The mean increase from baseline in HDL levels was ....
... reduced, with patients losing an average of 5.8 pounds. Serum lipid profiles were significantly improved, and there was a significant ... body weight was significantly reduced [-5.8+/-1.2 pounds], serum lipid profiles were significantly improved [total cholesterol -8.6+/-2.8 mg/dL; ...
... the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect. All influenza viruses are lipid enveloped viruses and not very resistant to inactivation. The H1N1 virus ...
... Site accessed September 19, 2008. (4) American Academy of Pediatrics. lipid Screening and Cardiovascular Health in Childhood, Cholesterol ... . Site accessed September 15, 2008. (5) American Academy of Pediatrics. lipid Screening and Cardiovascular Health in Childhood, Cholesterol ...
... trial to investigate the effect of Pantethine as a dietary supplement for lipid management and the reduction of cardiovascular risk factors in the North ... high quality ingredients can help individuals achieve a healthy blood lipid profile. "A large body of research points to Pantethine's effectiveness ...
... patients in placebo-controlled clinical trials. Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline. lipid alterations should be managed as clinically appropriate, particularly in ...
... of physiological and biochemical risk factors such as blood pressure and lipid profile. VH(R) IVUS measures the effects of investigational compounds on ... affects coronary plaque stability, as opposed to treating symptoms or lipid levels alone," said Scott Huennekens, President and CEO, Volcano Corp. ...
... the development of high blood sugars but also with abnormalities in the lipid profile and other biochemical changes which increase the risk of cardiovascular disease. Secondary endpoints included: change in lipid profile and abdominal obesity; glycemic control as measured by HbA1c; ...
... second study, which evaluated the effects of increasing doses of drug on lipid levels, confirms and extends the results of the previous study, and showed ... dose-dependent with regard to reductions on apoB-100 and atherogenic lipid levels, triglycerides, and atherosclerotic plaques. The maximum reduction ...
... indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ... individualized goal of therapy. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should ...
... indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ... individualized goal of therapy. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should ...
... evaluating among other endpoints, the impact of the Company's oxidized lipid metabolizing agent, ALT- 2074, on functional reverse cholesterol ... mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to ...
... were presented at the 16th International Symposium on Drugs Affecting lipid Metabolism being held October 4-7 in New York, NY. "It is exciting that ... role in the marketplace by providing clinicians another route to manage lipid disorders for patients who do not adequately respond to currently ...
... heart disease. Elevated levels of sPLA2 have been implicated in abnormal lipid metabolism, atherogenesis and vascular inflammation. The Company is ... develop A-002 in patients in need of novel therapies to improve their lipid profiles and reduce vascular damage due to inflammation." Data analysis ...
... Statin and Fibrate Combination in a Single Pill to Target Three Major lipid Components Moves Forward to Next Phase of Development ABBOTT PARK, Ill. ... medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ...
... platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator ... candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's ...
... GH has been found to decrease total body and regional fat mass in older men, while sex-steroids have been reported to have positive effects on lipid (fat) concentrations in the body. About Kronos Longevity Research Institute Kronos Longevity Research Institute (KLRI) is a ...
... discontinue therapy within 18 months due to either poor tolerability or incomplete efficacy. Metabolic safety, including weight gain, elevation of lipid levels (dyslipidemia) and glucose dysregulation, is an important consideration with any antipsychotic treatment. Patients often need to switch ...
... TRILIPIX 135 mg alone in patients with multiple lipid problems. Results from this new Phase III study ... combination of a fibrate with a statin to improve lipid levels. In the clinical trial, TRILIPIX ... More than 100 million American adults have lipid problems, and 35 percent reported being treated ...
Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
... The study, conducted by Tufts Medical Center lipid and health policy experts, was published in the ... ezetimibe/simvastatin combination to lower their lipid levels -- an issue that sparked many policy and ... of 4.1 per million prescriptions for other lipid lowering treatment. These rates demonstrate no ...New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity
... there is an urgent need for more comprehensive lipid control to protect against heart disease NEW ... (NHANES) database conducted by the National lipid Association (NLA) indicates that while Americans ... Jerome D. Cohen, M.D., chairman of the National lipid Association's consumer affairs committee ...VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis
... Detailed lipid profile helps clinicians identify risk in ... in understanding the risk for patients to develop lipid laden atheroma." The VAP Test provides ... VAP Test is the identification of the major lipid components of residual risk leading to proper ...... (rosuvastatin calcium) Demonstrates Similar lipid Effects in Patients with Diabetes and Overall ... This study, presented at the National lipid Association annual meeting on May 31, 2008, met ... in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had ...
... III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) ... III study were presented today at the National lipid Association's 2008 Scientific Sessions in ... Patients included in the study had multiple lipid problems, with an LDL greater than or equal to ...
First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
... with a newly cleared device to identify the lipid core (fatty) coronary plaques of interest that ... and help physicians identify those plaques with lipid cores, which may be of particular concern." ... The LipiScan System revealed the presence of a lipid core containing plaque not detectable by ...... uses near-infrared spectroscopy to identify lipid core containing plaques of interest in the ... effect of novel anti-atherosclerotic agents on lipid core plaque burden. "The InfraReDx team is ... "There is a real unmet medical need to identify lipid core containing plaques of interest in the ...
... III studies show that in patients with multiple lipid problems, Abbott's ABT-335 combined with two ... Patients included in the studies had multiple lipid problems, with an LDL greater than 130 ... clinical development for treating unhealthy lipid levels, including LDL cholesterol, triglycerides ...
... also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and ... were also measured with regard to efficacy, lipid effects, safety and tolerability. Additional ... in patients in the lopinavir/r arm. lipid Effects * Seven percent of patients in the ...
... XVI International Symposium on Drugs Affecting lipid Metabolism (DALM) (October 4-7, 2007, New York, ... interactions with five commonly prescribed lipid lowering compounds, opening the possibility for ... for the treatment of dyslipidemia (abnormal lipid levels in the bloodstream). Inhibiting the MTP ...
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
... the drug has the potential to improve a number of lipid parameters that are abnormal in different types ... job of targeting the entire range of different lipid disorders that contribute to cardiac risk. We ... MBX-8025 regulates fatty acid degradation, lipid storage/transport and insulin sensitivity. ...Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture
... help mask dry skin damage, they do not address the deeper problem of lipid damage caused during the cleansing process. Now with the introduction of ... research and testing has allowed us to be the first brand to minimize lipid damage with a liquid cleanser in order to provide intensive moisturizing ...... provides additional important data on the effect of VIRAMUNE on patient lipid profiles in antiretroviral naive patients." Efficacy Data ... and efficacy of once-daily dosing have not been established. lipid Profile Data The mean increase from baseline in HDL levels was ....
... reduced, with patients losing an average of 5.8 pounds. Serum lipid profiles were significantly improved, and there was a significant ... body weight was significantly reduced [-5.8+/-1.2 pounds], serum lipid profiles were significantly improved [total cholesterol -8.6+/-2.8 mg/dL; ...
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
... kg for overall lurasidone group vs. 0 kg for placebo) as was its effect on lipid and glucose measures. Lurasidone was also well tolerated with a lower ... tolerated with a low propensity for EPS, QTc interval changes and weight, lipid and glucose adverse effects. Adverse events seen in the three trials were ...... the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect. All influenza viruses are lipid enveloped viruses and not very resistant to inactivation. The H1N1 virus ...
Statins Lower Stroke Severity, Improve Recovery
... outcomes. The researchers say this shows benefits far beyond lowering lipid levels. Researchers think the specific benefits may include plaque ... months from March 2004 to December 2005. Among that number, 207 had their lipid levels measured within 15 days either side of the stroke incident -- and ...... Site accessed September 19, 2008. (4) American Academy of Pediatrics. lipid Screening and Cardiovascular Health in Childhood, Cholesterol ... . Site accessed September 15, 2008. (5) American Academy of Pediatrics. lipid Screening and Cardiovascular Health in Childhood, Cholesterol ...
... trial to investigate the effect of Pantethine as a dietary supplement for lipid management and the reduction of cardiovascular risk factors in the North ... high quality ingredients can help individuals achieve a healthy blood lipid profile. "A large body of research points to Pantethine's effectiveness ...
... patients in placebo-controlled clinical trials. Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline. lipid alterations should be managed as clinically appropriate, particularly in ...
... of physiological and biochemical risk factors such as blood pressure and lipid profile. VH(R) IVUS measures the effects of investigational compounds on ... affects coronary plaque stability, as opposed to treating symptoms or lipid levels alone," said Scott Huennekens, President and CEO, Volcano Corp. ...
... the development of high blood sugars but also with abnormalities in the lipid profile and other biochemical changes which increase the risk of cardiovascular disease. Secondary endpoints included: change in lipid profile and abdominal obesity; glycemic control as measured by HbA1c; ...
... second study, which evaluated the effects of increasing doses of drug on lipid levels, confirms and extends the results of the previous study, and showed ... dose-dependent with regard to reductions on apoB-100 and atherogenic lipid levels, triglycerides, and atherosclerotic plaques. The maximum reduction ...
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
... RNAi delivery system that combines proprietary chemical modification and lipid technologies to achieve efficient intracellular uptake without triggering ... (chemically modified siRNA molecules formulated in a proprietary lipid complex). In particular, Silence Therapeutics' AtuPLEX formulation was ...... indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ... individualized goal of therapy. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should ...
... indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ... individualized goal of therapy. The benefit of further alterations in lipid levels by the combined use of rosuvastatin with fibrates or niacin should ...
... evaluating among other endpoints, the impact of the Company's oxidized lipid metabolizing agent, ALT- 2074, on functional reverse cholesterol ... mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to ...
... were presented at the 16th International Symposium on Drugs Affecting lipid Metabolism being held October 4-7 in New York, NY. "It is exciting that ... role in the marketplace by providing clinicians another route to manage lipid disorders for patients who do not adequately respond to currently ...
Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
... These reductions and accompanying improvements in other atherogenic lipid levels were all relative to baseline levels which already reflected the ... for the many heterozygous FH patients who aren't able to achieve target lipid levels despite being treated with all that we currently have to offer ....... heart disease. Elevated levels of sPLA2 have been implicated in abnormal lipid metabolism, atherogenesis and vascular inflammation. The Company is ... develop A-002 in patients in need of novel therapies to improve their lipid profiles and reduce vascular damage due to inflammation." Data analysis ...
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
... create a lead antibody for pre- clinical development. LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and ... candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's ...... Statin and Fibrate Combination in a Single Pill to Target Three Major lipid Components Moves Forward to Next Phase of Development ABBOTT PARK, Ill. ... medication for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and ...
... platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator ... candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's ...
... GH has been found to decrease total body and regional fat mass in older men, while sex-steroids have been reported to have positive effects on lipid (fat) concentrations in the body. About Kronos Longevity Research Institute Kronos Longevity Research Institute (KLRI) is a ...
... discontinue therapy within 18 months due to either poor tolerability or incomplete efficacy. Metabolic safety, including weight gain, elevation of lipid levels (dyslipidemia) and glucose dysregulation, is an important consideration with any antipsychotic treatment. Patients often need to switch ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... for antiretroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown to have a more favorable lipid safety profile than other drugs in the PI class. The study is being sponsored by Schering-Plough with support from Bristol-Myers Squibb. ...Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
... About ARIKACE(TM) ARIKACE is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The ...FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
... glucose testing. Undesirable alterations in lipids have been observed with Zyprexa use. Clinical monitoring, including baseline and follow-up lipid evaluations in patients using Zyprexa, is advised. Clinically significant, and sometimes very high, elevations in triglyceride levels and modest mean ...Other ContentssprainssprainssprainssquamoussquamoussquamoussquamoussquamoussputumsputumspurspurspurspursquintsteinaureusaureusaureusaureusaureusaureusstaphylococcusstaphylococcusOther TagscannotCATICATICATICATICATICATICATICATIcollegesAMAAMAAMAAMAAMAAMASBIROther Tagsflowing 2flowing 3reproduce 2reproduce 3reproduce 4reproduce 5
(Date:12/1/2009)...Loneliness, like a bad cold, can spread among grou...o, the University of California-San Diego and Harv...-scale study that has been following health condit...und that lonely people tend to share their lonelin...onely, disconnected people moves to the fringes of...
(Date:11/30/2009)...The first comprehensive review of the state of Ant...al climate system is published this week (Tuesday ...ic Research (SCAR). The review - Antarctic Climat...research from the icy continent, identifies areas ...urgent questions that policy makers have about Ant...
(Date:11/30/2009)..., CLEMSON Clemson University researchers Ron Falt...ronmental Protection Agency grant to study the saf...ns located deep below the earth,s surface. , Wit...ls believed to be the leading cause of global warm...t promising alternatives for reducing emissions us...
Breaking Biology News(10 mins):Loneliness can be contagious 2Loneliness can be contagious 3First comprehensive review of the state of Antarctica's climate 2Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 1Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 2Celator 28R 29 Pharmaceuticals Presents Data on the Activity of CPX 351 Against Leukemia at the European Hematology Association Congress 12509 3Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2Metastorm Customer Wyeth Pharmaceuticals Wins CIO 100 Award for BPM Project 48143 1Metastorm Customer Wyeth Pharmaceuticals Wins CIO 100 Award for BPM Project 48143 2(Date:12/1/2009)...solating behaviors jump from friend to friend , ...w study suggests that lonely people attract fellow...oo. , "Loneliness can spread from person to per...," said James H. Fowler, co-author of the study pu...ersonality and Social Psychology , and professor o...
(Date:12/1/2009)...tar Institute researchers and collaborators from t...ity have identified immune system markers in the b...ple at high risk for developing lung cancer. The f...search , a journal of the American Association for...t to detect lung cancer in its earliest phases, wh...
(Date:12/1/2009)... of any medical, legal or business requiring dicta...ief this week with the release of ,DictateOnTheGo,... the holiday weekend, allows anyone required to di...ckly and seamlessly using just the iPhone 3G devic...2009 -- The iPhone App, released by Florida based ...
(Date:12/1/2009)...N.C., Dec. 1 Max Neeman Pharmacy s...ver the years serving the top most pharmaceutical ...lly set up in an area of 2000 sq. ft. has now doub...te of services by Max Neeman, are recognized by th..., The pharmacy inventory management process is ...
(Date:12/1/2009)... Air Products (NYSE: AP...ounced sale of the assets of its polyurethane pre-...4; and Versathane® tradenames to COIM USA Inc... chemicals producer COIM SpA. ,, Included in t...n Paulsboro, N.J. Terms of the agreement are not b...
Breaking Medicine News(10 mins):Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2[0] Loneliness May Be Catching[0] Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer[0] Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go'[0] Max Neeman International Expands Its Pharmacy Services Facility In Delhi[0] Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |